Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ATR 1072. This clearance enables the company to advance to its Corventis™ Phase 1/2 clinical trial, which aims to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. This marks the company's first precision cardiology program to enter clinical development, addressing a significant unmet medical need for this rare genetic cardiomyopathy.

Atrium Therapeutics, Inc. reported its first quarter 2026 financial results, including collaboration revenue of $19.6 million and a net loss of $(16.6) million. The company highlighted its recent launch as an independent public entity and the achievement of a $15 million milestone payment from Bristol Myers Squibb. Atrium Therapeutics also progressed its lead development program, ATR 1072, towards clinical trials and ended the quarter with a strong cash position of $267.8 million.